Targets › GAD2
1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Mar 2028.
Catalyzes the production of GABA. (UniProt, Q05329)
Open in Phaseline: the race on GAD2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Diamyd Medical | Diamyd GAD65 antigen therapy | GAD2 | Phase 2 | Diabetes Mellitus, Type 1 | Mar 2028 |
Diabetes Mellitus, Type 1 (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.